Aigen Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Aigen Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,594	Closed	-$44.1K	–	714
2026 Q1	$44.1K	Buy	+15,594	New	+$52.9K	0.01%	489
2025 Q2	–	Sell	-16,754	Closed	-$37K	–	968
2025 Q1	$37K	Buy	+16,754	New	+$66.2K	0.01%	722
2024 Q3	–	Sell	-30,192	Closed	-$216K	–	911
2024 Q2	$216K	Buy	30,192 +5,901	+24%	+$50.9K	0.04%	604
2024 Q1	$211K	Sell	24,291 -16,631	-41%	-$113K	0.05%	530
2023 Q4	$268K	Buy	+40,922	New	+$264K	0.05%	534
2023 Q2	–	Sell	-17,354	Closed	-$243K	–	897
2023 Q1	$243K	Buy	+17,354	New	+$249K	0.03%	477

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Aigen Investment Management's MRVI Position: Q2 2026 in Review

Aigen Investment Management sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 15,594 shares — an estimated $44.1K sold.

Aigen Investment Management first reported a position in MRVI in Q1 2023 and held it in 6 quarters. The position peaked at $268K in Q4 2023. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Aigen Investment Management reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
Aigen Investment Management sold 15,594 Maravai LifeSciences shares in Q2 2026, an estimated $44.1K.
Aigen Investment Management first reported a position in Maravai LifeSciences in Q1 2023 and held it in 6 quarters.
Aigen Investment Management's Maravai LifeSciences position peaked at $268K in Q4 2023.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.